CIPLA ATAZANAVIR atazanavir 200 mg capsule bottle pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

atazanavir sulfate, Quantity: 227.81 mg (Equivalent: atazanavir, Qty 200 mg)

Available from:

Cipla Australia Pty Ltd

INN (International Name):

Atazanavir sulfate

Pharmaceutical form:

Capsule, hard

Composition:

Excipient Ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; Gelatin; sodium lauryl sulfate

Administration route:

Oral

Units in package:

60 capsules, 30 capsules

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Atazanavir is indicated for the treatment of HIV 1 infection, in combination with other antiretroviral agents. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts from controlled studies (See Clinical Trials).

Product summary:

Visual Identification: White to pale yellow granules filled in size 0 hard gelatin capsule with maroon cap & white body spin printed with 'Cipla 200' on cap with white ink.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 15 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Authorization status:

Licence status A

Authorization date:

2017-08-30